BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Moberg Derma Obtains Approval For Seborrhoeic Eczema Product And Receives Iso 13485 Certification


4/13/2010 3:11:51 PM

Moberg Derma AB today announced that CE mark has been granted for its topical product for the management and relief of common scalp conditions associated with scaly and itchy skin, e.g. seborrhoeic eczema and dandruff. The CE mark provides authorization to market and sell the medical device product in the EU/EEA. The company also announced that it received ISO 13485 certification.

”We are now able to offer a new steroid-free treatment alternative in an indication area dominated by older products. The CE mark is a key milestone for the company and we look forward to making the product available to patients in collaboration with partners and distributors. The ISO 13485 certification is an important quality stamp of our operations”, says Moberg Derma's President and CEO, Peter Wolpert.

About the product and seborrhoeic dermatitis

The product is a prescription free topical solution indicated for the management of common scalp conditions such as seborrhoeic eczema and dandruff. Efficacy and safety have been demonstrated in several clinical studies including more than 300 patients. The product reduces itching and scaling and has a softening and moisturizing effect on the scalp.

Approximately 5% of the population suffers from seborrhoeic eczema of the scalp and skin. There is currently no cure for seborrhoeic eczema, which means that treatment focuses on minimizing symptoms, particularly scaling, erythema and itching.

Contact Moberg Derma

Peter Wolpert, President and CEO

Telephone: +46 8 - 522 307 00

Mobile: +46 70 - 735 71 35

E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB, Stockholm, Sweden, develops and commercializes patented medical products for the treatment of skin disorders. The company focuses on innovative products based on proven compounds. Moberg Derma outlicenses product rights to partners and distributors while maintaining certain promotion rights. The company began operations at the Karolinska Institute in 2006. The principal owners are Östersjöstiftelsen (the Baltic Sea Foundation), private investors and management. For further information, please visit: www.mobergderma.se


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES